0001209191-17-059629.txt : 20171107 0001209191-17-059629.hdr.sgml : 20171107 20171107170820 ACCESSION NUMBER: 0001209191-17-059629 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171107 FILED AS OF DATE: 20171107 DATE AS OF CHANGE: 20171107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jenkins Annalisa CENTRAL INDEX KEY: 0001639481 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37601 FILM NUMBER: 171184308 MAIL ADDRESS: STREET 1: C/O ARDELYX, INC. STREET 2: 34715 ARDENWOOD BLVD, SUITE 100 CITY: FREMONT STATE: CA ZIP: 94555 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dimension Therapeutics, Inc. CENTRAL INDEX KEY: 0001592288 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463942159 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-401-0011 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-11-07 1 0001592288 Dimension Therapeutics, Inc. DMTX 0001639481 Jenkins Annalisa C/O DIMENSION THERAPEUTICS, INC. 840 MEMORIAL DRIVE, 4TH FLOOR CAMBRIDGE MA 02139 1 1 0 0 President and CEO Stock Option (Right to Buy) 0.56 2017-11-07 4 D 0 481696 D 2024-09-24 Common Stock 481696 0 D Stock Option (Right to Buy) 3.57 2017-11-07 4 D 0 74375 D 2025-04-28 Common Stock 74375 0 D Stock Option (Right to Buy) 4.09 2017-11-07 4 D 0 342113 D 2025-06-02 Common Stock 342113 0 D Stock Option (Right to Buy) 7.14 2017-11-07 4 D 0 160000 D 2026-01-31 Common Stock 160000 0 D Stock Option (Right to Buy) 1.90 2017-11-07 4 D 0 192000 D 2027-01-31 Common Stock 192000 0 D Stock Option (Right to Buy) 1.35 2017-11-07 4 D 0 150000 D 2027-07-02 Common Stock 150000 0 D This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. This stock option, which vests over four years beginning June 3, 2015, at a rate of 6.25% on September 23, 2015, and in 45 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. This stock option, which vests in 48 equal monthly installments beginning January 28, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. This option, which vests on December 31, 2018, subject to the Reporting Person's continued service to the Issuer on such date, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. /s/ Mary Thistle, as Attorney-in-Fact for Annalisa Jenkins 2017-11-07